ArticleAmerican journal of translational research2026
Clinical follow-up and predictors of re-intervention following thoracic endovascular aortic repair for Stanford type B aortic dissection.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-Omics Identification and Validation of PCSK9 as a Candidate Molecule Associated with Aortic Dissection and Negative Remodeling After TEVAR.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study observed the clinical effect of Thoracic endovascular aortic repair (TEVAR) for Stanford Type B aortic dissection (TBAD) and identified predictors of re-intervention.
methodsA retrospective analysis was conducted on the clinical data of TBAD patients visiting the People's Hospital of Ningxia Hui Autonomous Region and undergoing TEVAR. Based on illness duration at the time of TEVAR, patients during the subacute or chronic phase were classified into the subacute group and chronic group. The changes in the aorta after the operation and the postoperative complications were evaluated. The risk factors for patients requiring further intervention were analyzed.
resultsWith a comparable incidence of postoperative complications, the subacute group showed better performance in terms of the false lumen thrombosis status and thrombus complete absorption rate. Postoperatively, the true lumen diameter at the left subclavian artery origin plane and the pulmonary artery bifurcation plane increased, while the false lumen diameter decreased. Multivariate logistic regression analysis showed that tubular graft (OR = 6.782, 95% CI = 1.668-27.582), graft length ≤145 mm (OR = 6.783, 95% CI = 1.623-28.348), postoperative false lumen expansion diameter >5 mm (OR = 6.906, 95% CI = 1.728-27.604), graft oversizing >15% (OR = 26.531, 95% CI = 5.800-121.370), and chronic-phase surgery (OR = 22.378, 95% CI = 2.987-167.637) were risk factors for re-intervention after TEVAR surgery.
conclusionTEVAR treatment for TBAD has certain short-term and mid-term efficacy, but the aortic remodeling effect is poor in patients in the chronic stage. Surgical timing, graft selection and its impact on false lumen expansion are risk factors for re-intervention after TEVAR surgery. Appropriate surgical timing and graft should be selected to avoid re-intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.